Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.